MicroRNA-577 promotes the sensitivity of chronic myeloid leukemia cells to imatinib by targeting NUP160.
To explore the effect of microRNA-577 on the drug sensitivity of chronic myeloid leukemia (CML) and the underlying mechanism. Quantitative Real Time-Polymerase Chain Reaction (qRT-PCR) was used to detect the expression of microRNA-577 in peripheral blood of patients with chronic myeloid leukemia. Meanwhile, the expression of microRNA-577 was detected in CML cell line after imatinib treatment. Cell counting kit-8 (CCK-8) and flow cytometry assay were applied to verify the effect of microRNA-577 on cell proliferation and cycle. NUP160 was identified as a target gene of microRNA-577 by dual-luciferase reporter gene assay. Cell reverse test was performed to figure out whether microRNA-577 can enhance the sensitivity of CML to imatinib. QRT-PCR results revealed that microRNA-577 level was notably decreased in peripheral blood of patients with CML, and microRNA-577 could inhibit the proliferation and cycle of CML cells. In addition, the result of dual-luciferase reporting assay indicated that microRNA-577 had a binding relationship with NUP160, and up-regulation of microRNA-577 in CML cell lines reduced the expression of NUP160, and vice versa. Lastly, cell reverse experiments confirmed that microRNA-577 can alleviate the resistance of CML to imatinib. We found that microRNA-577 promotes the sensitivity of chronic myeloid leukemia cells to imatinib by down-regulating the expression of NUP160.